Jump to Main Content
- Sakamoto, Kotaro; Koyama, Ryokichi; Kamada, Yusuke; Miwa, Masanori; Tani, Akiyoshi
- Biochemical and biophysical research communications 2018 v.503 no.3 pp. 1973-1979
- vasoactive intestinal peptide receptors, etc ; antagonists; binding capacity; calcium; central nervous system; drugs; humans; inhibitory concentration 50; ligands; mice; physiology; polypeptides; rats; schizophrenia; therapeutics; vasoactive intestinal peptide; Show all 16 Subjects
- ... Vasoactive intestinal peptide receptor 2 (VIPR2, also known as VPAC2) is a class B G-protein coupled receptor (GPCR) and plays important roles in the physiology of central nervous system (CNS) by interaction with natural ligands; vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). Because it has been reported that high-expression and/or overactivatio ...
- Valdehita, Ana; Carmena, María J.; Bajo, Ana M.; Prieto, Juan C.
- Molecular and cellular endocrinology 2012 v.348 no.1 pp. 241-246
- vasoactive intestinal peptide receptors, etc ; RNA interference; antagonists; breast neoplasms; epidermal growth factor receptors; erbB-2 receptor; humans; neoplasm cells; secretion; small interfering RNA; transcriptional activation; transfection; tyrosine; vascular endothelial growth factors; vasoactive intestinal peptide; Show all 15 Subjects
- ... We used small-interference RNA (siRNA) to explore the mechanisms of some vasoactive intestinal peptide (VIP) actions on human breast cancer cells. Transfection of estrogen-dependent (T47D) and estrogen-independent (MDA-MB-468) breast cancer cells with VPAC₁-receptor siRNA completely abolished VIP stimulatory effect on secretion of the main angiogenic factor, vascular endothelial growth factor (VEG ...